Transjugular intrahepatic portosystemic shunt (TIPS) is the first-line therapy for patients with cirrhosis and refractory ascites. However, mental changes known as hepatic encephalopathy (HE) frequently occur after TIPS. There is no effective method to predict HE after TIPS. Oral glutamine challenge (OGC) and psychometric tests have been used to assess the risk for HE, but never in patients undergoing TIPS. Severe muscle loss may also predispose patients to HE. The aim of the present study is to assess if both the OGC and psychometric tests can accurately predict the development of overt HE after TIPS. Patients will be studied before TIPS and followed after TIPS for the development of HE. The role of muscle loss in favoring HE, as well as is possible reversibility after TIPS will also be investigated.
In cirrhosis, up to 10% of patients develop refractory ascites. TIPS (transjugular intrahepatic portosystemic shunt) is the first-line therapy for these patients. However, 30% will go on to develop hepatic encephalopathy (HE) as a consequence of TIPS, and there is no effective method to predict this outcome. Oral glutamine challenge (OGC) is used to functionally assess ammonia metabolism, and the severity of porto-systemic collateralization, and it has been used to predict overt HE. Psychometric tests (i.e. Psychometric Hepatic Encephalopathy Score \[PHES\] and inhibitory control test) allow the identification of covert forms of HE and can also predict overt HE. Severe sarcopenia may also predispose patients to HE. The aim of the present study is to assess if both the degree of impairment in ammonia metabolism as estimated with the OGC, and cognitive status as determined by psychometric tests, can accurately predict the development of overt HE after TIPS. Patients will be studied before TIPS and followed after TIPS for the development of overt HE. The role of sarcopenia in favoring HE, as well as is possible reversibility after TIPS will also be investigated.
Study Type
OBSERVATIONAL
Enrollment
3
Blood ammonia determination before, 30-, 60-, and 90-minute, after intake of 10 g of L-glutamine
PHES (portosystemic hepatic encephalopathy score) and ICT (inhibitory control test)
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
University of Montreal
Montreal, Quebec, Canada
University Hospitals of Geneva
Geneva, Switzerland
Overt hepatic encephalopathy
Classified according to West Haven criteria.
Time frame: up to 18 months
Sarcopenia
According to CT scan L3 area of muscle mass
Time frame: Baseline and 6 months post-TIPS
Physical activity
Pedometer readings and physical activity questionnaire
Time frame: Baseline and 6 months post-TIPS
Dietary Intake
Food frequency questionnaire (FFQ, NutritionQuest, Berkeley, CA)
Time frame: Baseline and 6 months post-TIPS
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.